How Peptides Are Synthesized: Solid-Phase Peptide Synthesis Explained

Research peptides don’t occur naturally in the concentrations or purities suitable for laboratory use, they are manufactured through a precise chemical process called solid-phase peptide synthesis (SPPS). Understanding how peptides are synthesized illuminates the effort behind purity standards, the sources of common contaminants, and why manufacturing quality matters for research reproducibility. This guide covers the SPPS process from resin to final lyophilized product.

All information is provided for educational and research context only.

From Amino Acids to Peptide Chains: The Core Challenge

A peptide is a chain of amino acids linked by peptide bonds, covalent bonds formed between the carboxyl group (-COOH) of one amino acid and the amino group (-NH2) of the next, with the release of a water molecule. Building a specific sequence in a specific order, without unwanted side reactions between the multiple reactive functional groups present on amino acid side chains, is the central challenge of peptide chemistry.

Early solution-phase peptide synthesis required isolating and purifying products at every coupling step, a labor-intensive process that limited practical synthesis to very short sequences. The development of solid-phase peptide synthesis by Robert Bruce Merrifield in 1963 (for which he received the Nobel Prize in Chemistry in 1984) transformed the field by anchoring the growing peptide chain to an insoluble resin support, enabling automated, stepwise assembly with simple washing steps to remove reagents and byproducts between cycles.

Solid-Phase Peptide Synthesis (SPPS): Step by Step

1. Resin Selection and Loading

The synthesis begins with a polymeric resin, typically cross-linked polystyrene or polyethylene glycol-based (PEG) beads, functionalized with a linker group that will anchor the first amino acid and later release the completed peptide under defined conditions. Resin choice determines the C-terminal chemistry of the final product (free acid vs. amide) and the cleavage conditions required. Common resins include Wang resin (yields C-terminal free acid) and Rink amide resin (yields C-terminal amide, common for many bioactive peptides).

The first (C-terminal) amino acid is coupled to the resin under conditions that form a stable ester or amide linkage, establishing the anchor point from which the chain grows N-terminally.

2. Protecting Groups: Preventing Unwanted Reactions

Amino acids contain multiple reactive functional groups beyond the backbone amine and carboxyl, including side chain amines (lysine, arginine), carboxylates (aspartate, glutamate), hydroxyls (serine, threonine, tyrosine), thiols (cysteine), and imidazoles (histidine). If left unprotected, these groups would react indiscriminately during coupling, producing scrambled sequences and byproducts.

SPPS uses orthogonal protecting group strategies to mask reactive side chains during synthesis, removing them selectively at defined steps. The two dominant SPPS strategies are:

• Fmoc (9-fluorenylmethyloxycarbonyl) strategy: The most widely used modern approach. Fmoc protects the alpha-amine and is removed with piperidine (base-labile) between each coupling cycle. Side chain protecting groups are acid-labile, removed en masse during final cleavage with trifluoroacetic acid (TFA).
• Boc (tert-butyloxycarbonyl) strategy: Older approach; Boc is removed with TFA between cycles, and final deprotection/cleavage requires strong acid (hydrogen fluoride). Less common in modern research synthesis due to HF safety requirements, but used for certain applications and longer sequences.

3. The Coupling Cycle

With the resin loaded and protected, synthesis proceeds through repeated cycles, each adding one amino acid to the growing chain:

• Deprotection: The Fmoc group is removed from the N-terminus of the resin-bound peptide using piperidine solution, exposing the free amine for the next coupling
• Washing: The resin is washed thoroughly to remove piperidine and the released Fmoc-dibenzofulvene adduct
• Activation: The next amino acid (with its alpha-amine Fmoc-protected and side chains masked) is activated at its carboxyl group using coupling reagents such as HATU, HBTU, or DIC/Oxyma, forming a reactive ester that will react efficiently with the free amine
• Coupling: The activated amino acid is mixed with the resin, and the peptide bond forms between the activated carboxyl and the free amine. Coupling efficiency per cycle typically exceeds 99% with optimized conditions
• Washing: Excess reagents are washed away before the next deprotection step

This cycle repeats for each amino acid in the sequence, building the chain from C-terminus to N-terminus. A 30-amino acid peptide requires 30 complete coupling cycles. Modern automated synthesizers can complete each cycle in 15–45 minutes, enabling synthesis of moderately long peptides in 12–48 hours.

4. Cleavage and Global Deprotection

After the final coupling cycle, the completed peptide chain, still attached to the resin with all side chain protecting groups intact, is treated with a cleavage cocktail, typically TFA-based (e.g., TFA/triisopropylsilane/water). This simultaneously:

• Cleaves the peptide from the resin support
• Removes all acid-labile side chain protecting groups
• Scavengers mop up reactive carbocations released during deprotection, preventing reattachment to the peptide

The crude peptide is precipitated with cold diethyl ether, filtered, and dried, yielding a crude powder that contains the target peptide along with deletion sequences (where a coupling was incomplete), truncated sequences, side chain modification byproducts, and residual reagents.

5. Purification by HPLC

Crude SPPS products typically contain 60–90% target peptide by mass, with the balance being impurities. Achieving research-grade purity (≥98%) requires purification by reverse-phase high-performance liquid chromatography (RP-HPLC). The crude mixture is injected onto a C18 column and eluted with an acetonitrile/water gradient; the target peptide elutes at a characteristic retention time and is collected, while impurities of different hydrophobicity are separated. For high-purity research peptides, multiple HPLC passes may be required.

6. Analysis and Quality Control

Purified peptide is verified by two primary analytical techniques:

• Analytical HPLC: Confirms purity (the target peak as a percentage of total UV absorbance area). Research-grade peptides typically specify ≥98% purity.
• Mass spectrometry (MS): Confirms molecular weight and identity. Electrospray ionization (ESI-MS) or MALDI-TOF MS verify that the observed molecular mass matches the theoretical mass of the target sequence within acceptable tolerance.

A Certificate of Analysis (CoA) from a reputable manufacturer should include both the HPLC purity trace and the mass spectrum. Peptides lacking CoA documentation should not be used in quantitative research where compound identity and purity are experimental variables.

7. Lyophilization

The purified, confirmed peptide in aqueous solution is dispensed into vials and lyophilized (freeze-dried), frozen under vacuum until all water sublimes, leaving the peptide as a dry, stable powder. Lyophilization maximizes shelf life by removing water that would otherwise facilitate hydrolysis and microbial degradation. The white or off-white lyophilized powder is the final form in which research peptides are shipped and stored.

Special Considerations: Disulfide Bonds and Cyclic Peptides

Some research peptides, including BPC-157 (which contains no disulfide bonds) and others like oxytocin, insulin fragments, and conotoxins, require post-synthesis modifications. Disulfide bond formation between cysteine residues (as in AOD-9604) requires controlled oxidation under conditions that ensure correct pairing. Cyclic peptides require on-resin or solution-phase cyclization between specific residues. These modifications add complexity and cost to manufacturing but are essential for biological activity of the affected compounds.

Why Manufacturing Quality Matters for Research

Peptide synthesis impurities are not inert. Deletion sequences, peptides missing one or more residues, may have attenuated, absent, or antagonistic biological activity relative to the target compound. Racemized amino acids (where L-amino acids are converted to D-isomers during coupling) can significantly alter receptor binding and biological effects. Residual TFA and other synthesis reagents have known cytotoxic effects at the concentrations present in low-purity preparations.

For reproducible research, peptide purity and identity must be confirmed before use. A purity specification of ≥98% by HPLC and confirmed molecular weight by mass spectrometry are the minimum quality benchmarks for research-grade peptides.

References

• Merrifield, R. B. (1963). Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society, 85(14), 2149–2154.
• Chan, W. C., & White, P. D. (Eds.). (2000). Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press.
• Behrendt, R., White, P., & Offer, J. (2016). Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science, 22(1), 4–27.
• Isidro-Llobet, A., Álvarez, M., & Albericio, F. (2009). Amino acid-protecting groups. Chemical Reviews, 109(6), 2455–2504.

All content on this site is intended strictly for educational and research purposes. Products sold by Exceed Enhancement are for in vitro research use only, are not approved by the FDA, and are not intended for human consumption, therapeutic use, or veterinary application.